Local tumor progression following lipiodol-based targeted chemoembolization of hepatocellular carcinoma: a retrospective comparison of miriplatin and epirubicin.
Local tumor progression following lipiodol-based targeted chemoembolization of hepatocellular carcinoma: a retrospective comparison of miriplatin and epirubicin.
复制标题
DOI：
10.2147/cmar.s30431
复制
发表时间：
2012
影响因子：
3.3
通讯作者：
Mitani T
中科院分区：
文献类型：
--
作者：
Iwazawa J;Ohue S;Hashimoto N;Mitani T
我们的目的是比较米铂和表阿霉素在基于阿曲朵多的肝细胞癌（HCC）经动脉化疗栓塞（TACE）中的局部控制率。入组了接受靶向TACE的患者，使用米铂（47例患者，66处病变）或表阿霉素（64例患者，79处病变）作为唯一治疗。采用Kaplan-Meier估计量和对数秩检验比较局部控制率。使用考克斯比例风险模型对患者和肿瘤参数进行单变量和多变量分析。米铂组和表阿霉素组的总体局部复发率分别为39.3%和31.6%。表阿霉素组的局部控制率明显高于米铂组（P < 0.001）。6个月和1年时的局部控制率，米铂组分别为70.7%和44.8%，表阿霉素组分别为83.4%和69.2%。多变量分析显示，血清甲胎蛋白水平≥ 20 ng/mL（风险比2.96; P < 0.001）、使用米铂（风险比2.53; P = 0.002）和Child-Pugh分级B（风险比1.89; P = 0.042）影响局部进展。在HCC患者中，与表阿霉素相比，使用米铂的基于碘油的靶向TACE的局部控制率较差。
We aimed to compare the local control rates between miriplatin and epirubicin in lipiodol-based transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). Patients who underwent targeted TACE using miriplatin (47 patients, 66 lesions) or epirubicin (64 patients, 79 lesions) as the sole therapy were enrolled. The local control rates were compared using the Kaplan–Meier estimator with the log-rank test. The patient and tumor parameters were subjected to univariate and multivariate analyses using the Cox proportional hazards model. The overall local recurrence rates were 39.3% and 31.6% for the miriplatin and epirubicin groups, respectively. The local control rate was significantly higher in the epirubicin group than in the miriplatin group (P < 0.001). The local control rates at 6 months and 1 year were 70.7% and 44.8% for the miriplatin group and 83.4% and 69.2% for the epirubicin group, respectively. Multivariate analysis showed that the serum α-fetoprotein level ≥ 20 ng/mL (hazard ratio 2.96; P < 0.001), miriplatin usage (hazard ratio 2.53; P = 0.002), and Child-Pugh class B (hazard ratio 1.89; P = 0.042) affected local progression. Lipiodol-based targeted TACE using miriplatin had inferior local control rates as compared to epirubicin in patients with HCC.